Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Poxel's Total Liabilities for the quarter that ended in Jun. 2025 was €66.41 Mil. Poxel's Total Assets for the quarter that ended in Jun. 2025 was €5.00 Mil.
Therefore, Poxel's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2025 was 13.28.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Poxel Liabilities-to-Assets Related Terms
Poxel Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Poxel's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7PO vs VRTX, REGN, MRNA: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Poxel's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poxel Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poxel's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Poxel's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Poxel's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poxel (FRA:7PO) has a Liabilities-to-Assets of 13.28 as of Jun. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Poxel and its competitors.
Is Poxel's Liabilities-to-Assets too high?
Poxel's current Liabilities-to-Assets is 13.28. Overall, Poxel has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Poxel's Liabilities-to-Assets compare to VRTX and REGN?
Poxel's Liabilities-to-Assets of 13.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Poxel and its competitors. Poxel's current Liabilities-to-Assets is 13.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poxel stock overvalued right now?
Based on GuruFocus' analysis, Poxel (FRA:7PO) is currently considered Possible Value Trap. The stock's GF Value™ is €1.07, compared to a current price of €0.19 — trading 82.1% below its estimated fair value. The current Liabilities-to-Assets is 13.28. Poxel's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Poxel (FRA:7PO), the current Liabilities-to-Assets is 13.28 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poxel (FRA:7PO) Overvalued in 2026?
Based on GuruFocus' analysis, Poxel stock appears to be undervalued.
The current stock price of €0.19 is trading 82.1% below its estimated GF Value™ of €1.07.
GuruFocus considers Poxel to be Possible Value Trap.
Key valuation signals for FRA:7PO:
Liabilities-to-Assets: 13.28
GF Value™: €1.07 vs. price of €0.19 (82.1% below fair value)
No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
43GF Score
Get the complete analysis for FRA:7PO
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7PO has been successfully added to your 
